Himanshu Brahmbhatt, co-CEO of EnGeneIC, a biopharma company, talks about the company’s development of a first-in-class cyto-immunotherapy platform for targeted delivery of chemotherapeutics directly into tumors but limits harm to any healthy cells.
Dr. Himanshu Brahmbhatt co-founded EnGeneIC in 2001 with Dr. Jennifer MacDiarmid and took the company from a concept to now in clinical trials and the first end-stage mesothelioma patient in complete remission. Along the journey, they raised all the venture capital and private investor funds for the business operations, R and D, building a small-scale manufacturing plant and the three multi-center Phase I clinical trials with different EDV therapeutics in different end-stage cancers. They are also the sole inventors of EnGeneIC’s over 260 granted patents world-wide. Formerly Dr. Brahmbhatt was a Principal Research Scientist at the CSIRO. He has also undertaken post-doctoral research at the Geneva Medical Centre and the National Centre for Research and Biotechnology in Germany.